2cureX AB
GGETTEX:2QE0.04
EUR
+0.00
(-6.98%)
ISIN
SE0010468124
Return %
Stock
S&P 500
1Y
-79.25
14.20
3Y
-86.50
81.12
5Y
-97.41
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Semi-annual Revenue
SEK
•
in mil. unless spec.Semi-annual Earnings Per Share
SEK
•
in mil. unless spec.Semi-annual Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Ole Thastrup
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Copenhagen Denmark
- IPO Date
- Nov 24, 2017
- Website
- 2curex.com
- Similar Companies
- Business
- 2cureX AB is a Sweden-based biotechnology and precision oncology company specializing in functional diagnostic testing to guide individualized cancer treatment. Founded in 2006 and headquartered in Malmö, Sweden, with primary research, development, and laboratory operations conducted through its wholly owned subsidiary 2cureX A/S in Copenhagen, Denmark, the company focuses on the development and commercialization of 3D microtumor test systems for therapeutic decision support. 2cureX operates within the in vitro diagnostics and precision medicine sector, utilizing patient-derived tumoroids to measure functional sensitivity and resistance to oncology drugs. The company offers a systematic portfolio of proprietary diagnostic assays and analytical services, comprising: IndiTreat CRC, a CE-IVD certified functional test for predicting drug responses to standard chemotherapies and targeted therapies in metastatic colorectal cancer; IndiTreat mCRC, specialized drug profiling for late-stage colorectal cancer patients; IndiTreat Ovarian, a functional assay tailored to guide treatment selection in advanced and recurrent ovarian cancer; IndiTreat Pancreatic, a specialized assay under validation for therapeutic screening in pancreatic cancer; and Biopharma Functional Testing Services, providing custom assay development, compound screening, and drug response profiling for pharmaceutical and biotechnology partners conducting preclinical and clinical oncology research. The company targets oncologists, clinical cancer centers, hospital pathology departments, and biopharmaceutical developers across Europe, including Germany, the United Kingdom, Spain, Italy, France, and the Nordic countries, delivering tests through specialized centralized laboratory services and local testing setups. In recent major developments, 2cureX has expanded its commercial distribution network by establishing strategic distribution partnerships across multiple European and international markets to accelerate clinical adoption of the IndiTreat platform. In response to European regulatory updates, the company transitioned its diagnostic product portfolio toward compliance with the European Union In Vitro Diagnostic Regulation (IVDR) framework. Additionally, 2cureX has implemented operational restructuring and cost-efficiency programs to focus capital resources on commercialization, while actively pursuing strategic alliances, co-development agreements, and financing options to support clinical integration and market penetration.